Abbott Withdraws Psoriasis Drug Application
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott Laboratories is withdrawing its U.S. and European applications for experimental psoriasis drug briakinumab, citing regulators request for more research.
You may also be interested in...
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
Abbott Shaves U.S. Pharma Costs With Restructuring
Abbott plans to eliminate 1,900 positions, mainly within commercial and manufacturing, in a restructuring that will yield pre-tax savings of $200 million.
Abbott Shaves U.S. Pharma Costs With Restructuring
Abbott plans to eliminate 1,900 positions, mainly within commercial and manufacturing, in a restructuring that will yield pre-tax savings of $200 million.